Global Search

Hide Filters

Showing 1682 results

Press release / Sep 14, 2020

Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)

In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1…
Press release / Sep 30, 2021

Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions

Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and…
Press release / Jan 24, 2018

Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss

Novartis enters into a licensing and supply agreement to develop, register and commercialize investigational gene therapy voretigene neparvovec outside the US; Spark Therapeutics retains US rights…
Press release / Dec 23, 2015

Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients

Cosentyx (secukinumab) is the first IL-17A inhibitor approved in Europe to treat ankylosing spondylitis (AS) and first treatment advance in 16 years since anti-tumor necrosis factor (anti-TNF)…
Press release / Feb 27, 2026

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with…
Press release / Sep 11, 2017

Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified…
Press release / Dec 06, 2021

Bilateral transaction between Novartis and Roche successfully closed

Basel, December 6, 2021 — The bilateral transaction between Novartis and Roche for the sale of 53.3 million (approximately 33%) Roche bearer shares has successfully closed today, December 6, 2021.…
Press release / Oct 14, 2022

Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and…
Press release / Dec 06, 2015

Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations

Study in partnership with the Alliance for Clinical Trials in Oncology is the first large controlled trial to show overall survival benefit in FLT3-mutated AML AML is the most common acute…
Press release / Mar 28, 2020

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified…